Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.

We Need Your Support!

Backlinks from other websites and blogs are the lifeblood of our site and are our primary source of new traffic.

If you use our historical data on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. We have provided a few examples below that you can copy and paste to your site:

We Need Your Support!

Backlinks from other websites and blogs are the lifeblood of our site and are our primary source of new traffic.

If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. We have provided a few examples below that you can copy and paste to your site: